Skip to content

A double-blind randomized controlled trial of ''Qin-Re Li-Shi Tong-Luo'' approach in the treatment of Acute gouty arthritis

A double-blind randomized controlled trial of ''Qin-Re Li-Shi Tong-Luo'' approach in the treatment of Acute gouty arthritis

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2000003719
Enrollment
Unknown
Registered
2020-08-25
Start date
2020-10-01
Completion date
Unknown
Last updated
2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gout

Interventions

Sponsors

Yueyang Integrated traditional Chinese and Western Medicine Hospital affiliated to Shanghai University of traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: (1) Those who meet the diagnostic criteria of Western medicine for gouty arthritis and the diagnostic criteria of TCM syndromes; (2) Between 18-70 years old, male or female; (3) The acute attack was within 48 hours, and the baseline assessment showed that the total score of pain, tenderness and swelling was >= 5; (4) No non-steroidal anti-inflammatory drugs or drugs affecting uric acid metabolism were taken within one week before the observation; (5) Understand and agree to participate in this study and sign an informed consent form.

Exclusion criteria

Exclusion criteria: (1) Acute multi-joint gout involving more than 4 joints (2) complicated with osteoarthritis, rheumatoid arthritis and other arthritis diseases (3) Patients with severe primary diseases such as cardiovascular, cerebrovascular, liver, kidney and hematopoietic system, and mental illness; (4) patients with active gastrointestinal diseases and patients with digestive tract ulcers in the first 30 days of this study; (5) Those who are in critical condition and are difficult to make an accurate assessment of the effectiveness and safety of this clinical observation; (6) Those with severe deformity, stiffness, and loss of labor due to advanced arthritis; (7) Those who are known to be allergic to the drug used in this study.

Design outcomes

Primary

MeasureTime frame
VAS score;Safety and Tolerability of Polygonum Cuspidatum Gout Granules;

Secondary

MeasureTime frame
Researcher's overall evaluation of treatment response;Joint swelling (0-3 point scale);Patient's overall evaluation of response to treatment;Joint tenderness (0-3 point scale);

Countries

China

Contacts

Public ContactZhou Mi

Yueyang Integrated traditional Chinese and Western Medicine Hospital affiliated to Shanghai University of traditional Chinese Medicine

vieky2866@163.com+86 13636686022

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026